RetatrutidePeptide in clinical development
Retatrutide combines activity at GLP-1, GIP and glucagon receptors. Human trials provide a substantial weight-loss signal, while longer-term benefit and tolerability need their own assessment.
What is Retatrutide?
Retatrutide is an investigational peptide activating GLP-1, GIP and glucagon receptors. It is being studied for weight and metabolic outcomes.
How it works
Its three receptor activities combine appetite-related and metabolic signalling. The clinical effect needs to be measured rather than inferred from the number of targets.
Effects studied
Weight reduction
TRIUMPH-1 randomised 2,339 adults with obesity and without diabetes. At 80 weeks, mean weight changes with weekly retatrutide 4, 9 and 12 mg were −17.6%, −23.7% and −25.0%, compared with −3.9% on placebo. These are trial-group averages, not personal forecasts. Eli Lilly funded the trial. 3
Evidence: Phase 3 placebo-controlled trial; 2026 primary abstract reviewed
What does the evidence show?
Phase 3 placebo-controlled trial; 2026 primary abstract reviewed
Three signals in one molecule
Retatrutide acts at three hormone receptors involved in appetite and metabolism: GLP-1, GIP and glucagon. It is designed to combine complementary effects in one peptide. The number of receptors alone cannot rank medicines; the balance of activity and clinical results matter.
A substantial human signal
TRIUMPH-1 randomised 2,339 adults with obesity and without diabetes. At 80 weeks, mean weight changes with weekly retatrutide 4, 9 and 12 mg were −17.6%, −23.7% and −25.0%, compared with −3.9% on placebo. These are trial-group averages, not personal forecasts. Eli Lilly funded the trial. 3
Weight is one part of the question
The trial also assessed knee pain and sleep-apnoea outcomes in relevant subgroups. It did not compare retatrutide directly with semaglutide or tirzepatide, and weight loss alone cannot establish a longer life. 3
Tolerability helps determine real-world value
Gastrointestinal adverse events were the most common. The trial does not settle rare or longer-term risks, or establish the quality of online products sold under the same molecule name. 3
Safety & status
Gastrointestinal adverse events were the most common. The trial does not settle rare or longer-term risks, or establish the quality of online products sold under the same molecule name. 3
Country and product status
This introduction does not establish current marketing authorisation; research-stage and country-specific status require a current regulator check.
Frequently asked questions
Did TRIUMPH-1 show superiority to tirzepatide?
No. The comparator was placebo. 3
Does everyone lose 25% of their weight?
No. That was the average in one trial group after 80 weeks. 3
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Jastreboff et al. (2026): Retatrutide, a triple hormone receptor agonist, for treatment of obesity; TRIUMPH-1 Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.